Why Contracting with Specialty Pharmacies Could Seriously Grow Your 340B Referral Script Savings

SPONSORED CONTENT by Hannah Drake, Senior Director of Marketing, par8o

340B covered entities strive to ensure they are getting the maximum benefit out of the 340B program in order to help fund services for vulnerable patient populations. For health centers, this means setting up a robust contract pharmacy network.

Read More »

Judge Expresses Doubt About Government’s Position During Arguments in Novartis and United Therapeutics’ 340B Contract Pharmacy Lawsuits

U.S. District Judge Dabney Friedrich said today she agreed with another federal judge that the plain text of the 340B statute "doesn't speak" to contract pharmacy.

A federal district judge said today she “has a hard time following” the federal government’s argument that the 340B statute requires drug manufacturers to honor covered entities’ drug purchases no matter how entities choose to distribute the medicines.

“It seems

Read More »

Lifting of Title X Gag Rule Could Spur Hundreds of Clinics to Rejoin 340B

A September 2019 protest in Cleveland against the Trump administration rule barring Title X-funded family clinics from providing abortion referrals.

Hundreds of family planning clinics that lost their Title X federal grants and 340B eligibility because they opposed a Trump-era rule barring them from providing abortion referrals might return to Title X and 340B soon.

The U.S. Department of Health

Read More »

Feds Have Until Tomorrow to Oppose Sanofi’s Request for Stay Against 340B ADR Proceedings

U.S. Chief District Judge Freda Wolfson gave government lawyers until the end of the day tomorrow to weigh in on Sanofi’s request for emergency protection from 340B ADR proceedings.

A federal district judge has given government lawyers until Wednesday to weigh in on drug manufacturer Sanofi’s request for emergency protection from being brought before a 340B administrative dispute resolution panel.

U.S. Chief District Judge Freda Wolfson gave the U.S.

Read More »

CMS Rule that Will Set 340B Hospitals’ Part B Drug Reimbursement for 2022 Moves Closer to Release

The CMS final rule that will set Medicare reimbursement in 2022 to 340B hospitals for physician-administered drugs is another step closer to release.

The U.S. Centers for Medicare & Medicaid Services (CMS) final rule that will set what Medicare will pay 340B hospitals for physician-administered drugs next year is another step closer to release.

CMS last week Thursday sent its calendar year

Read More »

Managed Care Journal Article Gives 340B Hospitals Low Marks on Uncompensated Care

Researchers Sunita Desai (left) and J. Michael McWilliams, M.D., say they found no evidence that hospitals increased uncompensated care after entry into the 340B program any more than hospitals that never entered or had not yet entered the program.

Researchers who reported in 2018 that the 340B program leads to hospital-physician practice consolidation but probably not to better care or outcomes for low-income patients have released a new 340B study, this time on hospital provision of uncompensated care. The

Read More »

The 340B ACE Advantage: A Credential that Sets the Standard for 340B Expertise

SPONSORED CONTENT

When it comes to operating a 340B program, health systems, hospitals, and other entities that participate in the federal drug pricing program administered by HRSA have found that hiring graduates of the Apexus Advanced 340B Operations Certificate Program is helping them achieve compliance and implement a successful 340B program. 

In the

Read More »

Kalderos Sues HHS and HRSA, Says Ban on Drug Company Conditions on 340B Sales is Illegal

A mock-up of Request, one of the modules that make up Kalderos' 340B Pay service to enable drug manufacturers to provide 340B ceiling prices as rebates instead of as discounts.

Pharmaceutical industry vendor Kalderos has asked a federal court to vacate a federal health agency’s policy prohibiting drug manufacturers from conditioning 340B drug discounts on covered entities’ submission of drug claims data.

Kalderos has created a service called 340B

Read More »

Sanofi Seeks Emergency Stay Blocking 340B Dispute Resolution Proceedings

Drug manufacturer Sanofi yesterday asked a federal judge in New Jersey for an emergency stay against 340B administrative dispute resolution (ADR) proceedings against it brought by health centers.

Drug manufacturer Sanofi yesterday asked a federal judge in New Jersey to stay 340B administrative dispute resolution (ADR) proceedings against it brought by health centers seeking to overturn Sanofi’s restrictions on 340B pricing when covered entities use contract pharmacies.

Sanofi

Read More »

In Significant Development, HRSA Assigns Panels to Review 340B Dispute Resolution Claims Against Drug Companies

HRSA confirmed yesterday that 340B program administrative dispute resolution (ADR) panels have been assigned.

The U.S. Health Resources and Services Administration (HRSA) told 340B Report yesterday in response to an inquiry that 340B program administrative dispute resolution (ADR) panels have been assigned—signaling that an unknown number of proceedings might begin on ADR petitions by

Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report

Site Footer Live